AUROPHARMA — Aurobindo Pharma Income Statement
0.000.00%
Last trade - 00:00
- IN₹636.94bn
- IN₹629.12bn
- IN₹248.55bn
- 87
- 28
- 99
- 87
2019 March 31st | R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 195,636 | 230,985 | 247,746 | 234,555 | 248,554 |
Cost of Revenue | |||||
Gross Profit | 100,140 | 124,866 | 139,693 | 124,020 | 125,295 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 163,481 | 191,900 | 175,409 | 203,992 | 223,417 |
Operating Profit | 32,154 | 39,085 | 72,337 | 30,563 | 25,136 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 30,914 | 37,430 | 73,436 | 33,727 | 26,125 |
Provision for Income Taxes | |||||
Net Income After Taxes | 23,645 | 28,437 | 53,338 | 26,471 | 19,277 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 23,647 | 28,451 | 53,348 | 26,482 | 19,275 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 23,647 | 28,451 | 53,348 | 26,482 | 19,275 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 41.8 | 49.4 | 57.9 | 47.4 | 33 |
Dividends per Share |